ClinicalTrials.gg
RecruitingNCT05916430Updated Jun 4, 2026

Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement

An observational study in Autism and Infant Development, sponsored by Emory University. Recruiting at 2 sites in United States. Open to participants aged 8 Months to 10 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Emory University · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,120
Ages
8 Months to 10 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Autistic Disorder by Emory University — 5 open to participants now, 5 under way, none of them phase 3. Autistic Disorder · Emory University.

Started
2023
the only one that year
Observational
Only one
of the 10
Registered
7th of 10
by date

Among the 10 studies in Autistic Disorder by Emory University, this one is the only one that started in 2023, is the only observational one, and was the 7th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

5 of the 10 studies in Autistic Disorder by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 8 Months to 10 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Autistic Disorder by Emory University, or all of them as a file.
02

Study summary

The goal of this project is to measure the clinical utility of an objective and quantitative eye-tracking assay collected on a standalone, mobile investigational device to accurately screen 9-month-old infants for autism spectrum disorder and other actionable delays.

Read the detailed description

The purpose of this study is to see if measuring how infants look at social information can be used as a screening tool to identify developmental delays or vulnerabilities in infants as young as 9 months of age. What the 9-month-old infant looks at will be measured with eye-tracking technology, which uses a video camera to safely measure the child's eye movements while the child watches video scenes of other children at play. Parents/caregivers will be asked if they would like to participate during their child's 9-month well-baby visit at their pediatrician's office. If they agree to participate, the child will have their first study visit at this time. Children will undergo an eye-tracking session to measure social looking. Parents/caregivers will also complete forms and questionnaires about their child's health and development. The forms will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old.

If a child shows signs of developmental delay (DD) or autism spectrum disorder (ASD), the child will be asked to participate in a comprehensive developmental and diagnostic assessment in-person with expert clinicians when the child is between 18-26 months old, to determine the child's strengths and any vulnerabilities, and to recommend any support or treatment if needed.

If the child does not show signs of developmental delay and/or autism, the investigators may still invite the child for an in-person assessment with expert clinicians when the child is between 18-26 months old. Approximately 10% of children who do not show any signs of developmental delay and/or autism will be randomly selected for an in-person assessment. At the end of the assessment, parents/caregivers will be provided feedback on their child's strengths and any vulnerabilities and, if necessary, a report will be written to help them access services for their child.

03

Conditions studied

  • Autism
  • Infant Development

Keywords

  • Screening
  • well-baby visits
  • Social Development
  • Communicative Development
  • Development Disabilities
  • Autism Spectrum Disorders
04

Who can participate

Ages eligible
8 Months to 10 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Infants presenting for a 9-month well-child visit between the chronological ages of 8-10 months with no acute illnesses

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants between the chronological ages of 8-10 months
  • Infants must be generally healthy with no acute illnesses likely to prevent successful or valid data collection (e.g., current vomiting, high fever, conjunctivitis affecting vision)
  • Participants' parents/caregivers must be able to understand and voluntarily provide written .

Exclusion criteria

Exclusion Criteria:

- Children will be excluded if they have signs of acute illness likely to prevent successful or valid data collection (e.g., conjunctivitis affecting vision, current vomiting, or high fever).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,120 participants (estimated)
Patient registry
No

Groups and cohorts

  • General Population Screening Cohort

    A general population cohort of 9-month-old infants presenting for well-child visits will be screened initially at 9 months of age, and then screened again sequentially at 12, 15, 18, 21, and 24 months, to test screening performance relative to outcome status with autism or developmental disabilities.

    Diagnostic Test: EarliPoint Investigational Device

Interventions

  • Diagnostic testEarliPoint Investigational Device

    Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.

    Also known as: Screening test

06

What researchers measure

Primary outcomes

  1. Accuracy of eye-tracking assays at 9 months relative to ASD vs. non-ASD diagnosis at 24 months

    Diagnostic performance measured by sensitivity, specificity, area under the receiver operating characteristic curve, positive predictive value, and negative predictive value of the eye-tracking-based assays when compared with clinical reference standard diagnostic outcome of ASD or non-ASD.

    Time frame: 24 months

  2. Accuracy of eye-tracking assays at 9 months relative to Affected (ASD or DD) vs. Unaffected status at 24 months.

    Diagnostic performance measured by sensitivity, specificity, area under the receiver operating characteristic curve, positive predictive value, and negative predictive value of the eye-tracking-based assays when compared with clinical reference standard diagnostic outcome of Affected vs. Unaffected.

    Time frame: 24 months

Secondary outcomes

  1. Measure the ability of eye-tracking assays at 9 months to predict dimensional levels of social disability at 18-26 months compared to the Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2)

    Eye-tracking assays at 9 months will generate a social disability index; investigators will measure the correlation between that index and results on a standardized assessment by the ADOS-2 of autistic social disability conducted by expert clinicians at 18-26 months.

    Time frame: 18-26 months

  2. Measure the ability of eye-tracking assays at 9 months to predict dimensional levels of verbal ability at 18-26 months compared to the Mullen Scales of Early Learning

    Eye-tracking assays at 9 months will generate verbal ability indices; investigators will measure the correlation between those indices and results from a standardized assessment of expressive and receptive language function (the Mullen Scales of Early Learning). Receptive Language and Expressive Language Scales of the Mullen Scales of Early Learning (standardized measures of language function). Each item within these scales is scored either from 0 to 5 points for certain items or as 0 (skill not demonstrated) or 1 (correct response) for others. Raw scores are calculated by summing item-level ratings from the basal to the ceiling item. These raw scores are converted to standardized T-scores for analysis and interpretation (range: approximately 20-80 T-score; mean = 50, SD = 10; higher scores = better performance). The MSEL also yields an Early Learning Composite (mean = 100, SD = 15; higher scores = better overall performance).

    Time frame: 18-26 months

  3. Measure the ability of eye-tracking assays at 9 months to predict dimensional levels of nonverbal cognitive ability at 18-26 months.

    Eye-tracking assays at 9 months will generate nonverbal ability indices. Investigators will assess the correlation between those indices and results from the Visual Reception Scale of the Mullen Scales of Early Learning (a standardized measure of nonverbal cognitive function). Each item on the Visual Reception Scale is scored either from 0 to 5 points for certain items or as 0 (skill not demonstrated) or 1 (correct response) for others. Raw scores are calculated by summing item-level ratings from the basal to the ceiling item. These raw scores are converted to standardized T-scores for analysis and interpretation (range: approximately 20-80 T-score; mean = 50, SD = 10; higher scores = better performance).

    Time frame: 18-26 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data are planned to be publicly reposited in the NIMH Data Archive (https://nda.nih.gov) after publication, with accession number added when available.

Time frame: After publication

Access criteria: Access will follow standard NIMH NDA processes, as detailed on the website: https://nda.nih.gov/nda/faq.html

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.

Of 57 non-industry observational studies under Autistic Disorder, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 58 months is below that.

Counting every sponsor, half of 65 studies reached it within 43 months; a quarter within 20 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jun 23, 2023
StartActual
Feb 2, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05916430
Lead sponsor
Emory University
Responsible party
Warren R. Jones (Associate Professor, Emory University) — Principal investigator
First posted
Jun 23, 2023
Start date
Feb 2, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

FirstFocus Study
Contact
FirstFocus@emory.edu
404-785-4529
Warren R Jones, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion